Literature DB >> 10098343

Effect of 3 growth control substances on foreign body sarcomagenesis: IFN, IUdR, MGBG.

M Mhic Iomhair1, S M Lavelle.   

Abstract

The purpose was to observe the effect on sarcomagenesis of 3 substances reported to inhibit neoplastic growth--interferon alpha-2/alpha-1 hybrid (IFN), 5-iodo-2-deoxyuridine (IUdR) and methylglyoxal bis(guanylhydrazone) (MGBG). Inhibitory effect might help diminish the sarcoma risk of human implants. The substances were applied respectively to groups of 25mm cellulose filters which were implanted subcutaneously 1 per animal in randomly assigned respective groups of 50 female BALB/c mice. The implant sites were palpated weekly. On detection of a tumour the animal was sacrificed. The number of tumours arising and the accumulated weeks of exposure to the implants were recorded per group and compared to those of controls with untreated filters. Tumour incidence in the 2 IFN groups was 33/45 and 35/48 mice--160 per cent that of the controls, 22/48 (chi-square p < 0.05). In the IUdR group tumour incidence was 24/44 mice--194 per cent that of controls (p < 0.05), and in the MGBG group 15/43--122 per cent that of controls (p < 0.75). Although the substances inhibit tumour growth in man, they did not inhibit but increased film sarcomagenesis, not significant for MGBG. Observation of the effects of such substances with dual neoplastic activity may furnish clues to the control processes of neoplasia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098343     DOI: 10.1007/bf02939580

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  20 in total

1.  Etiological factors, stages, and the role of the foreign body in foreign body tumorigenesis: a review.

Authors:  K G Brand; L C Buoen; K H Johnson; I Brand
Journal:  Cancer Res       Date:  1975-02       Impact factor: 12.701

2.  Polymer tumorigenesis: clonal determination of histopathological characteristics during early preneoplasia; relationships to karyotype, mouse strain, and sex.

Authors:  K H Johnson; L C Buoen; I Brand; K G Brand
Journal:  J Natl Cancer Inst       Date:  1970-04       Impact factor: 13.506

3.  ROLE OF THE FIBROUS CAPSULE IN CARCINOGENESIS BY PLASTIC FILM.

Authors:  R R BATES; R T PREHN
Journal:  Nature       Date:  1965-01-16       Impact factor: 49.962

4.  Cellular attachment to implanted foreign bodies in relation to tumorigenesis.

Authors:  D J Ferguson
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

5.  Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival.

Authors:  K Mattson; A Niiranen; T Ruotsalainen; P Maasilta; M Halme; S Pyrhönen; M Kajanti; M Mäntylä; K Tamminen; A Jekunen; S Sarna; K Cantell
Journal:  J Interferon Cytokine Res       Date:  1997-02       Impact factor: 2.607

6.  Action of histone on neoplastic and normal growth.

Authors:  S M Lavelle
Journal:  Ir J Med Sci       Date:  1973-03       Impact factor: 1.568

7.  Enhancing and inhibiting effects of histone fractions on film sarcoma.

Authors:  S M Lavelle; M Maclomhair
Journal:  Ir J Med Sci       Date:  1978-04       Impact factor: 1.568

8.  Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial.

Authors:  A M Levine; A Tulpule; D Tessman; L Kaplan; F Giles; B D Luskey; D T Scadden; D W Northfelt; I Silverberg; J Wernz; B Espina; D Von Hoff
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

9.  Characterization of cellular response to silicone implants in rats: implications for foreign-body carcinogenesis.

Authors:  S J James; M Pogribna; B J Miller; B Bolon; L Muskhelishvili
Journal:  Biomaterials       Date:  1997-05       Impact factor: 12.479

10.  Pharmacokinetic profile of Mitoguazone (MGBG) in patients with AIDS related non-Hodgkin's lymphoma.

Authors:  J Rizzo; A M Levine; G R Weiss; T Pearce; M Kraynak; R Mueck; S Smith; D D Von Hoff; J G Kuhn
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.